Agilent Technologies Inc vs Huntington Ingalls Industries Inc — how do they compare? Agilent Technologies Inc trades at $149.35 (market cap $42.00B), while Huntington Ingalls Industries Inc trades at $328 (market cap $13.04B). The key difference: Agilent Technologies Inc is far larger — about 3.2× Huntington Ingalls Industries Inc's market cap, and Huntington Ingalls Industries Inc pays the higher dividend (1.67%). Which is the better fit depends on your goals.
| A | HII | |
|---|---|---|
Market Cap | $42.00B | $13.04B |
Sector | Health | Technology |
52-Week High | $157.20 | $453.73 |
52-Week Low | $110.24 | $265.40 |
Enterprise Value | $43.55B | $15.96B |
Dividend Yield | 0.69% | 1.67% |
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $145.97, up 3.28% in the last session, with a bullish technical outlook from moving averages but overbought RSI levels. The company reported strong Q1 2026 earnings, beating estimates with EPS of $1.49, and maintains solid profitability with a net income margin of 19.55%. Recent developments include FDA and EU approvals for diagnostic assays and the acquisition of Biocare Medical, enhancing its healthcare portfolio.
The stock offers upside to the consensus price target of $154.90, supported by analyst optimism (77.5% buy ratings), but high valuation ratios like a P/E of 146.56 pose risks. Investors should monitor execution of growth initiatives and competitive pressures in the life sciences sector, with earnings on August 26, 2026, as a key catalyst.
HII trades at $324.48, up 0.85% on the day, with a bullish technical signal driven by moving averages and recent contract wins. The company reported strong Q2 2026 results, beating EPS estimates with $5.27 versus $3.79 expected, and revenue growth of 10.9%. Key developments include a $900 million robotics partnership and new submarine contracts, supporting a positive outlook.
The stock offers upside to the consensus price target of $359.67, with 44% of analysts rating it Buy. Risks include execution challenges in shipbuilding and political headwinds. Fundamentals are solid with a P/E of 19.7 and ROE of 12.97%, but overbought RSI levels near 85.92 suggest near-term caution.
Trailing returns across standard periods
Latest headlines on both assets
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →Huntington Ingalls is the largest military shipbuilder in the U.S. and a provider of professional services to government and industry partners, specializing in nuclear-powered submarines and aircraft carriers.
Read more on HII →